Release Kinetics of RhBMP-2 Using E-PRF As an Autologous Carrier: an in Vitro Analysis

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Dec 10, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a special growth factor called rhBMP-2, which helps with bone healing, and how it can be delivered using a product made from a patient's own blood called enhanced Platelet-rich fibrin (E-PRF). The researchers want to see how well rhBMP-2 sticks to E-PRF and how quickly it is released over time in a lab setting. They will also compare this method to a currently approved carrier, an absorbable collagen sponge (ACS), and look at combinations of both E-PRF and ACS.

To be eligible for this study, participants need to be at least 18 years old, able to speak and understand English, and a patient at the UAB Dental School. They should also be scheduled for a dental procedure that requires a blood draw, which is part of the usual care. Importantly, the study is not yet recruiting participants, and those who smoke heavily or have certain health issues that could affect healing may not be eligible. Participants will be required to read and understand a consent document explaining the study. Overall, this research aims to improve the ways we help patients heal from bone loss during dental procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • English speaking
• • At least 18 years old
• • Must be a patient of the UAB Dental School
• • Able to read and understand informed consent document
• • Previously treatment planned for a periodontal procedure that will utilize PRF, i.e. requiring venipuncture, as a part of the routine clinical care.
• Exclusion Criteria:
• • Non-English speaking
• • Less than 18 years old
• • Smokers/tobacco users (\>10 cigarettes/day)
• • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing as assessed by Board Certified Periodontal faculty at UAB Department of Periodontology
• • Patient-reported serious adverse events reported with venipuncture, blood sample collection, and/or blood donation.